JP2005506061A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506061A5
JP2005506061A5 JP2003514002A JP2003514002A JP2005506061A5 JP 2005506061 A5 JP2005506061 A5 JP 2005506061A5 JP 2003514002 A JP2003514002 A JP 2003514002A JP 2003514002 A JP2003514002 A JP 2003514002A JP 2005506061 A5 JP2005506061 A5 JP 2005506061A5
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
composition according
disease
gland
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003514002A
Other languages
English (en)
Japanese (ja)
Other versions
JP4587667B2 (ja
JP2005506061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/001106 external-priority patent/WO2003008444A2/en
Publication of JP2005506061A publication Critical patent/JP2005506061A/ja
Publication of JP2005506061A5 publication Critical patent/JP2005506061A5/ja
Application granted granted Critical
Publication of JP4587667B2 publication Critical patent/JP4587667B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003514002A 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド Expired - Lifetime JP4587667B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30615001P 2001-07-19 2001-07-19
US30616101P 2001-07-19 2001-07-19
US33147701P 2001-11-16 2001-11-16
PCT/CA2002/001106 WO2003008444A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Publications (3)

Publication Number Publication Date
JP2005506061A JP2005506061A (ja) 2005-03-03
JP2005506061A5 true JP2005506061A5 (https=) 2006-01-05
JP4587667B2 JP4587667B2 (ja) 2010-11-24

Family

ID=27405149

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2003514002A Expired - Lifetime JP4587667B2 (ja) 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Country Status (22)

Country Link
US (2) US7192929B2 (https=)
EP (2) EP1417227B1 (https=)
JP (4) JP2005507647A (https=)
KR (2) KR100966232B1 (https=)
CN (1) CN100475843C (https=)
AT (1) ATE353914T1 (https=)
AU (2) AU2002319050B2 (https=)
BR (2) BR0211199A (https=)
CA (2) CA2453965C (https=)
CY (1) CY1108009T1 (https=)
DE (2) DE60217507T2 (https=)
DK (1) DK1417228T3 (https=)
EA (1) EA006603B1 (https=)
ES (2) ES2281528T3 (https=)
IL (2) IL159903A0 (https=)
MX (1) MXPA04000561A (https=)
NO (1) NO333999B1 (https=)
NZ (2) NZ531115A (https=)
PL (1) PL207588B1 (https=)
PT (1) PT1417228E (https=)
WO (2) WO2003008444A2 (https=)
ZA (1) ZA200401320B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
AU2002304314B2 (en) * 2001-03-08 2007-09-06 Nyomox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
IL159903A0 (en) * 2001-07-19 2004-06-20 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE60234047D1 (de) * 2001-12-04 2009-11-26 Millenium Pharmaceuticals Inc 15603, ein mitglied der humanen ionenkanal-familie
CA2529777A1 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US20080227125A1 (en) * 2003-07-15 2008-09-18 Guilaine Argoud-Puy Secreted Polypeptide Species Reduced in Cardiovascular Disorders
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
EP1994152B1 (en) 2006-02-28 2012-12-12 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EA200801942A1 (ru) * 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
JP5572938B2 (ja) * 2007-10-25 2014-08-20 東レ株式会社 免疫誘導剤
AU2008314925B2 (en) * 2007-10-25 2013-11-07 Toray Industries, Inc. Immune response inducer
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
KR20110015571A (ko) * 2008-04-24 2011-02-16 더리무넥 파마큐티컬스, 아이엔씨. 펩티딜 디아실글리세라이드
EP3409287B9 (en) 2010-09-29 2021-07-21 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2015063613A2 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
CA3096978A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006993A1 (en) 1988-12-21 1990-06-28 The General Hospital Corporation Method of detecting neurological disease or dysfunction
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
CA2282729A1 (en) * 1997-02-26 1998-09-03 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
AU765110B2 (en) * 1998-06-26 2003-09-11 Georgetown University Medical Center Compositions and methods for inducing cell death
AU2185199A (en) * 1998-09-30 2000-04-17 Yoko Aida Apoptosis inducers
AU2373800A (en) * 1998-12-11 2000-06-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
JP2002542766A (ja) * 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
WO2000063230A2 (en) * 1999-03-26 2000-10-26 Human Genome Sciences, Inc. 49 human secreted proteins
JP2002543764A (ja) * 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４６個のヒト分泌タンパク質
JP2003535570A (ja) 1999-03-26 2003-12-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
AU3769700A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 45 human secreted proteins
CN1300779A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) * 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
WO2002000718A2 (en) * 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
CN1352145A (zh) * 2000-11-10 2002-06-05 上海博德基因开发有限公司 一种新的多肽——锌指蛋白14.08和编码这种多肽的多核苷酸
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
DK1390403T3 (da) * 2001-05-25 2007-05-14 Nymox Corp Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf
IL159903A0 (en) * 2001-07-19 2004-06-20 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Similar Documents

Publication Publication Date Title
JP2005506061A5 (https=)
JP2005521383A5 (https=)
JP2005507647A5 (https=)
JP2004534533A5 (https=)
ES2342416T3 (es) Procedimiento de purificacion o produccion de una proteina mage.
JP2004529908A5 (https=)
CN105705522B (zh) 针对低免疫原性蛋白的表位疫苗及其制法和用途
CN102596217B (zh) 经修饰的血管活性肠肽
JP2003531632A (ja) グルカゴンアンタゴニスト
US20080057064A1 (en) Erbb3 Based Methods and Compositions for Treating Neoplasms
EP2281040B1 (en) Lyophilized dna formulations for enhanced expression of plasmid dna
JPH06502771A (ja) 筋細胞内での発現のためのウイルス性組換え型ベクター
JP2005530484A5 (https=)
JP2002524078A (ja) 子宮頸がんの治療
US20210403948A1 (en) Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof
JPWO2019140283A5 (ja) アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
JP2004528266A (ja) 薬物送達用組成物
JP2006517104A (ja) トランスポゾンに基づく標的化システム
PT98695A (pt) Gene codificador do factor neurotrofico de ligacao a heparina
RU2013113639A (ru) Иммунотерапевтический способ лечения рака простаты
JP2002505847A (ja) Ｒｈｉｐｉｃｅｐｈａｌｕｓａｐｐｅｎｄｉｃｕｌａｔｕｓ由来の組織セメントタンパク質
CN100435848C (zh) 提高饲料效率和家畜生长速度的基因处理
JPWO2020084162A5 (https=)
CN118141903A (zh) 一种治疗犬黑色素瘤的环状rna疫苗
ES2302731T3 (es) Compuestos y procedimientos para reducir los niveles de colesterol sin inducir hipertrigliceridemia.